<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37242988</PMID><DateRevised><Year>2023</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>23</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>Long COVID and Hybrid Immunity among Children and Adolescents Post-Delta Variant Infection in Thailand.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">884</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines11050884</ELocationID><Abstract><AbstractText>This study aimed to assess long COVID, and describe immunogenicity against Omicron variants following BNT162b2 vaccination. A prospective cohort study was conducted among children (aged 5-11) and adolescents (aged 12-17) who had SARS-CoV-2 infection from July to December 2021 (Delta predominant period). Long COVID symptoms were assessed by questionnaires at 3 months after infection. Immunogenicity was evaluated by using a surrogate virus-neutralizing antibody test (sVNT) against the Omicron variant. We enrolled 97 children and 57 adolescents. At 3 months, 30 children (31%) and 34 adolescents (60%) reported at least one long COVID symptom, with respiratory symptoms prevailing (25% children and 32% adolescents). The median time from infection to vaccination was 3 months in adolescents and 7 months in children. At 1 month following vaccination, in children who received one-dose and two-dose BNT162b2 vaccines, the median (IQR) sVNT against Omicron was 86.2% inhibition (71.1-91.8) and 79.2% inhibition (61.5-88.9), respectively (<i>p</i> = 0.26). Among adolescents who received one-dose and two-dose BNT162b2 vaccines, the median (IQR) sVNT against Omicron was 64.4% inhibition (46.8-88.8) and 68.8% inhibition (65.0-91.2) (<i>p</i> = 0.64). Adolescents had a higher prevalence of long COVID than children. Immunogenicity against the Omicron variant after vaccination was high and did not vary between one or two doses of the vaccine in either children or adolescents.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jarupan</LastName><ForeName>Muttharat</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jantarabenjakul</LastName><ForeName>Watsamon</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0003-4251-3499</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence for Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Thai Red Cross Emerging Infectious Diseases Clinical Center, King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaruampornpan</LastName><ForeName>Peera</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Monoclonal Antibody Production and Application Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), Pathum Thani 12120, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subchartanan</LastName><ForeName>Jarujan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phasomsap</LastName><ForeName>Chayapa</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center of Excellence for Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sritammasiri</LastName><ForeName>Taweesak</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center of Excellence for Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cartledge</LastName><ForeName>Sapphire</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5554-1512</Identifier><AffiliationInfo><Affiliation>School of Medicine, University of Birmingham, Birmingham B15 2TT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchartlikitwong</LastName><ForeName>Pintip</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-4153-161X</Identifier><AffiliationInfo><Affiliation>Center of Excellence for Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anugulruengkitt</LastName><ForeName>Suvaporn</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6965-5537</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence for Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawichai</LastName><ForeName>Surinda</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center of Excellence for Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puthanakit</LastName><ForeName>Thanyawee</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-1873-1867</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center of Excellence for Pediatric Infectious Diseases and Vaccines, Department of Pediatrics, Chulalongkorn University, Bangkok 10330, Thailand.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RA65/032</GrantID><Agency>Chulalongkorn University</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BNT162b2</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Delta</Keyword><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 infection</Keyword><Keyword MajorTopicYN="N">anti-SARS-CoV-2 IgG</Keyword><Keyword MajorTopicYN="N">hybrid immunity</Keyword><Keyword MajorTopicYN="N">long COVID in children</Keyword><Keyword MajorTopicYN="N">neutralizing antibody titer</Keyword><Keyword MajorTopicYN="N">post COVID-19 conditions</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>27</Day><Hour>9</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>27</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>27</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37242988</ArticleId><ArticleId IdType="pmc">PMC10223729</ArticleId><ArticleId IdType="doi">10.3390/vaccines11050884</ArticleId><ArticleId IdType="pii">vaccines11050884</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization  WHO Coronavirus Disease (COVID-19) Dashboard. 2023.  [(accessed on 12 April 2023)].  Available online:  https://covid19.who.int.</Citation></Reference><Reference><Citation>Lopez-Leon S., Wegman-Ostrosky T., Ayuzo Del Valle N.C., Perelman C., Sepulveda R., Rebolledo P.A., Cuapio A., Villapol S. Long-COVID in children and adolescents: A systematic review and meta-analyses. Sci. Rep. 2022;12:9950. doi: 10.1038/s41598-022-13495-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-13495-5</ArticleId><ArticleId IdType="pmc">PMC9226045</ArticleId><ArticleId IdType="pubmed">35739136</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention  Long COVID or Post COVID Conditions.  [(accessed on 6 April 2023)]; Available online:  https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html.</Citation></Reference><Reference><Citation>O&#x2019;Mahoney L.L., Routen A., Gillies C., Ekezie W., Welford A., Zhang A., Karamchandani U., Simms-Williams N., Cassambai S., Ardavani A., et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis. EClinicalMedicine. 2022;55:101762. doi: 10.1016/j.eclinm.2022.101762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101762</ArticleId><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Borel M., Xie L., Kapera O., Mihalcea A., Kahn J., Messiah S.E. Long-term physical, mental and social health effects of COVID-19 in the pediatric population: A scoping review. World J. Pediatr. 2022;18:149&#x2013;159. doi: 10.1007/s12519-022-00515-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12519-022-00515-7</ArticleId><ArticleId IdType="pmc">PMC8812346</ArticleId><ArticleId IdType="pubmed">35118594</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau E.H., Hui D.S., Tsang O.T., Chan W.H., Kwan M.Y., Chiu S.S., Cheng S.M., Ko R.L., Li J.K., Chaothai S., et al. Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection. EClinicalMedicine. 2021;41:101174. doi: 10.1016/j.eclinm.2021.101174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101174</ArticleId><ArticleId IdType="pmc">PMC8556690</ArticleId><ArticleId IdType="pubmed">34746725</ArticleId></ArticleIdList></Reference><Reference><Citation>Renk H., Dulovic A., Seidel A., Becker M., Fabricius D., Zernickel M., Junker D., Gro&#xdf; R., M&#xfc;ller J., Hilger A., et al. Robust and durable serological response following pediatric SARS-CoV-2 infection. Nat. Commun. 2022;13:128. doi: 10.1038/s41467-021-27595-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27595-9</ArticleId><ArticleId IdType="pmc">PMC8748910</ArticleId><ArticleId IdType="pubmed">35013206</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheatley A.K., Juno J.A., Wang J.J., Selva K.J., Reynaldi A., Tan H.X., Lee W.S., Wragg K.M., Kelly H.G., Esterbauer R., et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat. Commun. 2021;12:1162. doi: 10.1038/s41467-021-21444-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21444-5</ArticleId><ArticleId IdType="pmc">PMC7896046</ArticleId><ArticleId IdType="pubmed">33608522</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan K., Karim F., Cele S., Reedoy K., San J.E., Lustig G., Tegally H., Rosenberg Y., Bernstein M., Jule Z., et al. Omicron infection enhances Delta antibody immunity in vaccinated persons. Nature. 2022;607:356&#x2013;359. doi: 10.1038/s41586-022-04830-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04830-x</ArticleId><ArticleId IdType="pmc">PMC9279144</ArticleId><ArticleId IdType="pubmed">35523247</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W., Huo J., Zhou D., Zahradn&#xed;k J., Supasa P., Liu C., Duyvesteyn H.M.E., Ginn H.M., Mentzer A.J., Tuekprakhon A., et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022;185:467&#x2013;484.e15. doi: 10.1016/j.cell.2021.12.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.12.046</ArticleId><ArticleId IdType="pmc">PMC8723827</ArticleId><ArticleId IdType="pubmed">35081335</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall V., Foulkes S., Insalata F., Kirwan P., Saei A., Atti A., Wellington E., Khawam J., Munro K., Cole M., et al. Protection against SARS-CoV-2 after COVID-19 Vaccination and Previous Infection. N. Engl. J. Med. 2022;386:1207&#x2013;1220. doi: 10.1056/NEJMoa2118691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118691</ArticleId><ArticleId IdType="pmc">PMC8908850</ArticleId><ArticleId IdType="pubmed">35172051</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food &amp; Drug Administration  FDA News Release: FDA Approves First COVID-19 Vaccine August 23, 2021.  [(accessed on 12 October 2022)]; Available online:  https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration  FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age.  [(accessed on 12 October 2022)];2021 October 29; Available online:  https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age.</Citation></Reference><Reference><Citation>Crotty S. Hybrid immunity, COVID-19 vaccine responses provide insights into how the immune system perceives threats. Science. 2021;372:392&#x2013;393.</Citation></Reference><Reference><Citation>Reynolds C.J., Pade C., Gibbons J.M., Butler D.K., Otter A.D., Menacho K., Fontana M., Smit A., Sackville-West J.E., Cutino-Moguel T., et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science. 2021;372:1418&#x2013;1423. doi: 10.1126/science.abh1282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abh1282</ArticleId><ArticleId IdType="pmc">PMC8168614</ArticleId><ArticleId IdType="pubmed">33931567</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu Jabal K., Ben-Amram H., Beiruti K., Batheesh Y., Sussan C., Zarka S., Edelstein M. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: Real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Eurosurveillance. 2021;26:2100096. doi: 10.2807/1560-7917.ES.2021.26.6.2100096.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2021.26.6.2100096</ArticleId><ArticleId IdType="pmc">PMC7879501</ArticleId><ArticleId IdType="pubmed">33573712</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel R.R., Apostolidis S.A., Painter M.M., Mathew D., Pattekar A., Kuthuru O., Gouma S., Hicks P., Meng W., Rosenfeld A.M., et al. Distinct antibody and memory B cell responses in SARS-CoV-2 na&#xef;ve and recovered individuals following mRNA vaccination. Sci. Immunol. 2021;6:eabi6950. doi: 10.1126/sciimmunol.abi6950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abi6950</ArticleId><ArticleId IdType="pmc">PMC8158969</ArticleId><ArticleId IdType="pubmed">33858945</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer F., Srivastava K., Alshammary H., Amoako A.A., Awawda M.H., Beach K.F., Berm&#xfa;dez-Gonz&#xe1;lez M.C., Bielak D.A., Carre&#xf1;o J.M., Chernet R.L., et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N. Engl. J. Med. 2021;384:1372&#x2013;1374. doi: 10.1056/NEJMc2101667.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2101667</ArticleId><ArticleId IdType="pmc">PMC8008743</ArticleId><ArticleId IdType="pubmed">33691060</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention  Stay Up to Date with COVID-19 Vaccines Including Boosters.  [(accessed on 19 November 2022)]; Available online:  https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html.</Citation></Reference><Reference><Citation>Tan C.W., Chia W.N., Qin X., Liu P., Chen M.I., Tiu C., Hu Z., Chen V.C., Young B.E., Sia W.R., et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat. Biotechnol. 2020;38:1073&#x2013;1078. doi: 10.1038/s41587-020-0631-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-020-0631-z</ArticleId><ArticleId IdType="pubmed">32704169</ArticleId></ArticleIdList></Reference><Reference><Citation>Amanat F., Stadlbauer D., Strohmeier S., Nguyen T.H.O., Chromikova V., McMahon M., Jiang K., Arunkumar G.A., Jurczyszak D., Polanco J., et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 2020;26:1033&#x2013;1036. doi: 10.1038/s41591-020-0913-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0913-5</ArticleId><ArticleId IdType="pmc">PMC8183627</ArticleId><ArticleId IdType="pubmed">32398876</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng S., Phillips D.J., White T., Sayal H., Aley P.K., Bibi S., Dold C., Fuskova M., Gilbert S.C., Hirsch I., et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 2021;27:2032&#x2013;2040. doi: 10.1038/s41591-021-01540-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01540-1</ArticleId><ArticleId IdType="pmc">PMC8604724</ArticleId><ArticleId IdType="pubmed">34588689</ArticleId></ArticleIdList></Reference><Reference><Citation>De Santis G.C.F., Mendrone A., Langhi D., Jr., Covas D.T., Fabron A., Jr., Cortez A.J.P., Dinardo C.L., Ubiali E.M.A., Marques J.F.C., Jr., Bordin J.O., et al. Suggested guidelines for convalescent plasma therapy for the treatment of COVID-19. Hematol. Transfus. Cell Ther. 2021;43:212&#x2013;213. doi: 10.1016/j.htct.2021.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.htct.2021.03.001</ArticleId><ArticleId IdType="pmc">PMC7980204</ArticleId><ArticleId IdType="pubmed">33778377</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrino R., Chiappini E., Licari A., Galli L., Marseglia G.L. Prevalence and clinical presentation of long COVID in children: A systematic review. Eur. J. Pediatr. 2022;181:3995&#x2013;4009. doi: 10.1007/s00431-022-04600-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-022-04600-x</ArticleId><ArticleId IdType="pmc">PMC9476461</ArticleId><ArticleId IdType="pubmed">36107254</ArticleId></ArticleIdList></Reference><Reference><Citation>Munblit D., Bobkova P., Spiridonova E., Shikhaleva A., Gamirova A., Blyuss O., Nekliudov N., Bugaeva P., Andreeva M., DunnGalvin A., et al. Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID-19. Clin. Exp. Allergy. 2021;51:1107&#x2013;1120. doi: 10.1111/cea.13997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cea.13997</ArticleId><ArticleId IdType="pmc">PMC8444748</ArticleId><ArticleId IdType="pubmed">34351016</ArticleId></ArticleIdList></Reference><Reference><Citation>Borch L., Holm M., Knudsen M., Ellermann-Eriksen S., Hagstroem S. Long COVID symptoms and duration in SARS-CoV-2 positive children&#x2014;A nationwide cohort study. Eur. J. Pediatr. 2022;181:1597&#x2013;1607. doi: 10.1007/s00431-021-04345-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-021-04345-z</ArticleId><ArticleId IdType="pmc">PMC8742700</ArticleId><ArticleId IdType="pubmed">35000003</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuekprakhon A., Nutalai R., Dijokaite-Guraliuc A., Zhou D., Ginn H.M., Selvaraj M., Liu C., Mentzer A.J., Supasa P., Duyvesteyn H.M.E., et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell. 2022;185:2422&#x2013;2433.e13. doi: 10.1016/j.cell.2022.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.06.005</ArticleId><ArticleId IdType="pmc">PMC9181312</ArticleId><ArticleId IdType="pubmed">35772405</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin D.Y., Gu Y., Xu Y., Zeng D., Wheeler B., Young H., Sunny S.K., Moore Z. Effects of Vaccination and Previous Infection on Omicron Infections in Children. N. Engl. J. Med. 2022;387:1141&#x2013;1143. doi: 10.1056/NEJMc2209371.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2209371</ArticleId><ArticleId IdType="pmc">PMC9511630</ArticleId><ArticleId IdType="pubmed">36069811</ArticleId></ArticleIdList></Reference><Reference><Citation>Puthanakit T., Chantasrisawad N., Yoohat K., Nantanee R., Sophonphan J., Meepuksom T., Sodsai P., Phanthanawiboon S., Jantarabenjakul W., Hirankarn N., et al. Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents. Vaccines. 2022;10:1646. doi: 10.3390/vaccines10101646.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10101646</ArticleId><ArticleId IdType="pmc">PMC9609361</ArticleId><ArticleId IdType="pubmed">36298510</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>